Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.

Ramachandran G, Bhavani PK, Hemanth Kumar AK, Srinivasan R, Raja K, Sudha V, Venkatesh S, Chandrasekaran C, Swaminathan S.

Int J Tuberc Lung Dis. 2013 Dec;17(12):1564-8. doi: 10.5588/ijtld.13.0390.

PMID:
24200269
2.

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.

Zhang J, Zhu L, Stonier M, Coumbis J, Xu X, Wu Y, Arikan D, Farajallah A, Bertz R.

J Antimicrob Chemother. 2011 Sep;66(9):2075-82. doi: 10.1093/jac/dkr266. Epub 2011 Jun 28.

3.

Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.

Naiker S, Connolly C, Wiesner L, Kellerman T, Reddy T, Harries A, McIlleron H, Lienhardt C, Pym A.

BMC Pharmacol Toxicol. 2014 Nov 19;15:61. doi: 10.1186/2050-6511-15-61.

4.

Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.

Mallolas J, Sarasa M, Nomdedeu M, Soriano A, López-Púa Y, Blanco JL, Martínez E, Gatell JM.

HIV Med. 2007 Mar;8(2):131-4.

5.

Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA.

Clin Infect Dis. 2009 Nov 1;49(9):1305-11. doi: 10.1086/606056.

6.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
7.

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C.

Int J Tuberc Lung Dis. 2012 Jan;16(1):6-15. doi: 10.5588/ijtld.10.0626. Epub 2011 Aug 3. Review.

PMID:
21819645
8.

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

Lan NT, Thu NT, Barrail-Tran A, Duc NH, Lan NN, Laureillard D, Lien TT, Borand L, Quillet C, Connolly C, Lagarde D, Pym A, Lienhardt C, Dung NH, Taburet AM, Harries AD.

PLoS One. 2014 Jan 22;9(1):e84866. doi: 10.1371/journal.pone.0084866. eCollection 2014.

9.

A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.

Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW.

Clin Pharmacol Ther. 2001 Aug;70(2):149-58.

PMID:
11503009
10.

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.

Le Tiec C, Barrail A, Goujard C, Taburet AM.

Clin Pharmacokinet. 2005;44(10):1035-50. Review.

PMID:
16176117
11.

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.

Moultrie H, McIlleron H, Sawry S, Kellermann T, Wiesner L, Kindra G, Gous H, Van Rie A.

J Antimicrob Chemother. 2015 Feb;70(2):543-9. doi: 10.1093/jac/dku382. Epub 2014 Oct 3.

12.

Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.

Di Biagio A, Rosso R, Loregian A, Pagni S, Sormani MP, Cenderello G, Palù G, Viscoli C.

J Infect Chemother. 2012 Aug;18(4):587-90. doi: 10.1007/s10156-012-0402-y. Epub 2012 Mar 16.

PMID:
22422300
13.

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.

Weiner M, Benator D, Peloquin CA, Burman W, Vernon A, Engle M, Khan A, Zhao Z; Tuberculosis Trials Consortium.

Clin Infect Dis. 2005 Nov 1;41(9):1343-9. Epub 2005 Sep 29.

14.

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Ripamonti D, Cattaneo D, Maggiolo F, Airoldi M, Frigerio L, Bertuletti P, Ruggeri M, Suter F.

AIDS. 2007 Nov 30;21(18):2409-15.

PMID:
18025877
15.

Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.

Tanuma J, Sano K, Teruya K, Watanabe K, Aoki T, Honda H, Yazaki H, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Aug 5;8(8):e70611. doi: 10.1371/journal.pone.0070611. Print 2013.

16.

Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.

Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA; Tuberculosis Trials Consortium.

Pharmacotherapy. 2007 Jun;27(6):793-800.

PMID:
17542762
17.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL.

AIDS. 2004 Jun 18;18(9):1291-7.

PMID:
15362661
18.

Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.

Li RC, Narang PK, Sahai J, Cameron W, Bianchine JR.

Antimicrob Agents Chemother. 1997 Jul;41(7):1566-70.

19.

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.

Cato A 3rd, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R.

Clin Pharmacol Ther. 1998 Apr;63(4):414-21.

PMID:
9585795
20.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
Items per page

Supplemental Content

Write to the Help Desk